At the Extraordinary General Meeting of Shareholders held on March 5, 2026, RedHill Biopharma Ltd. shareholders approved grants of restricted share units to non-executive directors, CEO and Chairman Dror Ben-Asher, and Chief Commercial Officer and Director Rick D. Scruggs, and an increase in the Company's authorized share capital.
Key takeaways
Extraordinary General Meeting held on March 5, 2026
All proposed resolutions duly approved
RSUs granted to non-executive directors, each RSU representing one American Depository Share (10,000 ordinary shares)
RSUs granted to Dror Ben-Asher, Chief Executive Officer and Chairman
RSUs granted to Rick D. Scruggs, Chief Commercial Officer and Director